Dr. Jing Li, PhD, MB
Executive Director, WuXi Biology San Diego Site Head Conventional Small Molecules, RNA-Targeting Small Molecules, Other Small Molecule Drugs, Molecular Glue Degrader, Other Proximity-Induced Modifiers, Target Discovery, Target Validation, HTS/HCS, Oncology, Immunology, Inflammatory Disease, Autoimmune Disease, Cellular Assay, Biochemical Assay
Dr. Jing Li joined WuXi Biology as Executive Director in 2024 to lead US teams to provide end-to-end biology services and solutions. Before that, he served as Executive Director PTC Therapeutics, and Chief Scientific Officer at Eternity Bioscience, Inc., and at the Jiangsu Hengrui Medicine US R&D Site. Jing worked at Merck Research Laboratories for fifteen years with various roles and responsibilities. Jing received his PhD in Microbiology and Immunology from Medical College of Pennsylvania and an MB in Medicine from Shanghai Medical University. Jing discovered the novel tumor suppressor gene, PTEN, while he was postdoctoral fellow at Columbia University. Jing has co-authored over 50 scientific and patent publications which have appeared in journals like Science and Nature Genetics.